Immatics NV (IMTX) Stock Forecast & Price Target

Immatics is well positioned for upside because its dual-modality PRAME franchise combines a potentially registrational autologous cell therapy, anzu-cel, with an off-the-shelf bispecific, IMA402, giving it two shots on goal in a biologically compelling target that is expressed in nearly all melanomas. Anzu-cel’s Phase 3 SUPRAME trial has a high probability of success, supported by encouraging Phase 1b durability, a more convenient outpatient-friendly regimen, and potential manufacturing and randomization dynamics that could favor its PFS readout expected in 1H27. Financially, Immatics had about $448 million in cash as of 2Q26 and raised another $150 million in August 2026, providing runway into 2028 while key catalysts such as ESMO 2026 and a possible 2027 BLA submission de-risk the broader melanoma opportunity.

Immatics is negative because its value proposition remains highly dependent on clinical data that are still uncertain, with SUPRAME’s slower-than-expected event accrual forcing protocol amendments and pushing final PFS data into 1H27 and BLA submission into 2027. The company also faces major execution risk from safety, regulatory, and operational hurdles, including leukapheresis bottlenecks, potential bridging and censoring issues, and the challenge of proving superiority against active controls in earlier-line settings where the bar is materially higher. Financially, it reported €453.6 mm of cash on 31 March, but the outlook still anticipates dilution via an offering following disclosure of SUPRAME data in 2026, while competitive and intellectual-property risks further cloud commercialization.